Kamada (KMDA) Other financing activities (2013 - 2026)
Kamada (KMDA) posted quarterly Other financing activities of -$467000.0 for Q1 2026, down 43.69% year-on-year from -$829371.6 in Q1 2025, and up 55.14% on a QoQ basis from -$1.0 million in Q4 2025.
Kamada (KMDA) Other financing activities (2013 - 2026) Analysis & Trends
Kamada (KMDA) has reported Other financing activities for 10 consecutive years, with -$467000.0 the latest figure, recorded in Q1 2026.
- Quarterly Other financing activities fell 43.69% year-over-year to -$467000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.0 million (up 19.54% YoY) and the FY2025 annual result came in at -$5.9 million, up 53.51% from the prior year.
- Other financing activities improved to -$467000.0 in Q1 2026 per KMDA's latest filing, from -$1.0 million in the prior quarter.
- Over the last five years, Other financing activities for KMDA reached as high as -$877.0 in Q3 2022 and fell as low as -$11.5 million in Q3 2023.
- A 5-year average of -$2.4 million and a median of -$1.5 million in 2022 frame the typical range for Other financing activities.
- The largest YoY upside for Other financing activities was 99.9% in 2023 against a maximum downside of 1311188.48% in 2023.
- Year by year, Other financing activities stood at -$1.5 million in 2022, then rose by 0.4% to -$1.5 million in 2023, then jumped by 76.6% to -$351000.0 in 2024, then sank by 196.58% to -$1.0 million in 2025, then surged by 55.14% to -$467000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered -$467000.0, -$1.0 million, and -$339000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -467,000.00 |
| Mar 31, 2026 | -467,000.00 |
| Dec 31, 2025 | -1.04 Mn |
| Dec 31, 2025 | -1.04 Mn |
| Sep 30, 2025 | -339,000.00 |
| Sep 30, 2025 | -339,000.00 |
| Jun 30, 2025 | -4.18 Mn |
| Jun 30, 2025 | -4.18 Mn |
| Mar 31, 2025 | -325,000.00 |
| Mar 31, 2025 | -325,000.00 |
| Dec 31, 2024 | -351,000.00 |
| Dec 31, 2024 | -351,000.00 |
| Sep 30, 2024 | -4.47 Mn |
| Sep 30, 2024 | -4.47 Mn |
| Jun 30, 2024 | -2.35 Mn |
| Jun 30, 2024 | -2.35 Mn |
| Mar 31, 2024 | -5.50 Mn |
| Mar 31, 2024 | -5.50 Mn |
| Dec 31, 2023 | -1.50 Mn |
| Dec 31, 2023 | -1.50 Mn |